Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide and its impact in dermatology

D I Stirling1

  • 1Celgene Corporation, Warren, NJ 07059, USA.

Seminars in Cutaneous Medicine and Surgery
|December 22, 1998
PubMed
Summary

Thalidomide, initially a sedative, is now a crucial treatment for dermatologic conditions like erythema nodosum leprosum (ENL). With careful use, it effectively treats various skin disorders, including those linked to HIV.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.

Cellular signalling·2014
Same author

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

British journal of pharmacology·2010
Same author

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

British journal of cancer·2004
Same author

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.

Leukemia·2003
Same author

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.

Leukemia·2001
Same author

Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.

Journal of clinical immunology·2001

Area of Science:

  • Pharmacology
  • Dermatology
  • Teratology

Background:

  • Thalidomide was initially marketed as a sedative in 1956 and gained popularity due to its perceived safety profile.
  • Reports of severe congenital abnormalities led to its withdrawal in 1961.
  • It later found a niche in dermatology for treating erythema nodosum leprosum (ENL) in leprosy patients.

Purpose of the Study:

  • To review the historical context and evolving therapeutic applications of thalidomide.
  • To highlight its efficacy in various dermatologic conditions beyond ENL.
  • To discuss its biological actions and potential as a therapeutic option when used with safety precautions.

Main Methods:

  • Literature review of thalidomide's historical use and clinical studies.
  • Analysis of reported biological actions, including TNF-alpha inhibition.
  • Examination of its effectiveness in treating specific dermatologic disorders.

Main Results:

  • Thalidomide is now the drug of choice for erythema nodosum leprosum (ENL).
  • Its effectiveness is documented in aphthous stomatitis, discoid lupus erythematosus, actinic prurigo, Behçet's disease, and prurigo nodularis.
  • It has also shown utility in HIV-associated dermatologic conditions.

Conclusions:

  • Thalidomide possesses diverse biological actions, including TNF-alpha inhibition, contributing to its efficacy.
  • When administered with safeguards against teratogenicity and peripheral neuropathy, it offers a valuable therapeutic option.
  • It remains an important treatment for specific dermatologic conditions where other therapies have failed.

Related Experiment Videos